Fedratinib – November 2025 – May 2026

Fedratinib: Capsule 100 mg; Inrebic®

Brand names:
- Inrebic®
Pharmaceutical Company:
- BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD
Condition/Indication: Myelofibrosis
Meeting Date: May 2026
Public Summary Document (PSD) November 2025 May 2026 PBAC Meetings - (PDF 941.9KB)
Public Summary Document (PSD) November 2025 May 2026 PBAC Meetings - (Word 207.8KB)

Last updated

14 September 2026